Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients.
The immunogenicity of a recombinant yeast-derived hepatitis B vaccine was evaluated in a randomized trial involving 80 haemodialysis patients in which three 40 microgram doses were administered according to either a 0, 1, 2 month, or a 0, 1, 6 month vaccination schedule. The vaccine induced an anti-HBs seroconversion in 54% of patients who received the three doses at intervals of one month (Group A) and in 55% of those who were vaccinated at months 0, 1, and 6 (Group B). The geometric mean titres (GMT) seven months after the first injection were 37.7 IU/l in Group A and 91 IU/l in Group B. The seroconversion rate in men (53.6%) was slightly lower than in women (60%), and the respective GMTs were 33.3 and 78.5 IU/l. An age-dependent effect was noted in the anti-HBs response, but the type of renal disease and length of time on dialysis did not influence the antibody response. A 0, 1, and 2 month vaccination schedule seems preferable for haemodialysis patients as it induces more rapid protection.
Bruguera
M
M
Liver Unit, Hospital Clinic i Provincial, Barcelona, Spain.
Cremades
M
M
Mayor
A
A
Sánchez Tapias
J M
JM
Rodés
J
J
D000367:Age Factors; D000941:Antigens / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant / Q000276:immunology; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D006435:Renal Dialysis; D012441:Saccharomyces cerevisiae / Q000235:genetics; D012737:Sex Factors; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000941:Antigens; D004274:DNA, Recombinant; D006510:Hepatitis B Antibodies; D014614:Vaccines, Synthetic